{"result": {"id": "chatcmpl-470", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"The Eye on Cancer Research Community\",\n    \"summary\": \"This community focuses on research and treatment of cancer, particularly in the context of eye diseases. It features a network of researchers, clinicians, and institutions working together to advance knowledge and develop new therapies for patients with ocular cancers. The community's core entities are linked through collaborations, shared data, and clinical trials, highlighting their interconnectedness in tackling this complex disease.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The Eye on Cancer Research Community exhibits a high level of impact due to its focus on a critical area of healthcare (cancer) with significant implications for patient well-being and the advancement of medical knowledge. The community's interconnectedness and collaborative efforts contribute to a substantial impact on research, treatment, and ultimately, patient care.\",\n    \"findings\": [\n        {\n            \"summary\": \"The community is driven by a strong focus on ocular cancers, with researchers actively investigating various types of eye cancer and their unique challenges.\",\n            \"explanation\": \"This community's core focus lies in the research and treatment of ocular cancers. Researchers are dedicated to understanding the complexities of these cancers, exploring new diagnostic techniques, and developing innovative therapies for patients. This dedication is evident through collaborations between researchers, clinicians, and institutions working together to advance knowledge and develop effective treatments. The community's efforts are focused on improving patient outcomes and addressing the specific challenges associated with ocular cancer.\"\n        },\n        {\n            \"summary\": \"Collaboration is a cornerstone of this community, fostering innovation and accelerating progress in research and treatment.\",\n            \"explanation\": \"The Eye on Cancer Research Community thrives on collaboration. Researchers from various institutions work together to share data, expertise, and resources. This collaborative approach allows for the development of more comprehensive studies, leading to faster breakthroughs in understanding and treating ocular cancers. The community's commitment to collaboration is evident through shared research platforms, joint clinical trials, and open communication channels.\"\n        },\n        {\n            \"summary\": \"Clinical trials are a vital component of this community, providing opportunities for patients to access new treatments and contribute to scientific advancements.\",\n            \"explanation\": \"Clinical trials play a crucial role in the Eye on Cancer Research Community. These trials offer patients access to cutting-edge therapies while simultaneously contributing valuable data to advance medical knowledge. The community's commitment to clinical trials ensures that patients are at the forefront of research, benefiting from the latest advancements and contributing to the development of more effective treatments.\"\n        },\n        {\n            \"summary\": \"The community is actively engaged in developing new diagnostic tools and treatment strategies for ocular cancers.\",\n            \"explanation\": \"This community's dedication to innovation is evident through its efforts to develop novel diagnostic tools and treatment strategies. Researchers are working on improving existing techniques, exploring new technologies, and developing innovative therapies tailored to the specific needs of patients with ocular cancer. This commitment to progress ensures that patients receive the most effective treatments available.\"\n        },\n        {\n            \"summary\": \"The community's impact extends beyond research and treatment, influencing policy and public awareness regarding ocular cancers.\",\n            \"explanation\": \"This community's influence extends beyond the realm of research and treatment. The community actively engages in advocating for policies that support patients with ocular cancer and raising public awareness about this often-overlooked disease. This advocacy ensures that patients receive adequate care and resources, while also promoting a greater understanding of ocular cancers within the broader community.\"\n        }\n    ]\n} \n\n\n\n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743288266, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 733, "prompt_tokens": 2048, "total_tokens": 2781, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n1352,BEVACIZUMAB,\"**Bevacizumab** is an anti-angiogenic drug used to treat various conditions, including certain cancers and eye conditions. It inhibits angiogenesis, the formation of new blood vessels, by targeting vascular endothelial growth factor (VEGF).  It is commonly prescribed for treating **CoNV**, a condition where it helps inhibit tumor growth. Bevacizumab can also be used to treat GI bleeding. \n\",16\n1356,PAZOPANIB,Pazopanib is a medication used to treat certain cancers,4\n1367,ENDOSCOPIES,Number of endoscopies performed on patients with cancer,4\n2434,FTD/TPI,Treatment regimen for patients with mCRC,3\n2500,OTHER TREATMENTS,,3\n2418,TRIFLURIDINE/TIPIRACIL,Drug used in the TRUSTY study,1\n2495,VISUAL ACUITY,\"**Visual acuity** can improve after treatment, specifically with the use of **bevacizumab**. This improvement is a documented effect of the treatment. \n\",1\n2496,CO-NV,A measure of the severity of eye disease,1\n2497,GRAFT REJECTION,Rejection of a transplanted organ,1\n2498,FAILURE RATE,The rate at which patients fail to respond to treatment with bevacizumab,1\n2485,CORNEAL NEOVASCULARIZATION,\"**Corneal neovascularization (CNV)** is a medical condition characterized by abnormal growth of blood vessels on the cornea, leading to impaired corneal transparency and vision impairment.  It is a significant contributor to blindness, often serving as a heavy attribute in blinding diseases. CNV can be caused by various factors, including alkali burns, and its underlying mechanisms are being studied through research focusing on molecules involved in the process. This condition is considered a vision-threatening disease, with corneal neovascularization being the second major cause of blindness globally. \n\",12\n2486,VEGETA GROWTH FACTOR INHIBITORS,Anti-VEGF drugs are used to prevent Corneal neovascularization,4\n5290,INVASIVE DRUG INJECTIONS,Another common treatment for CNV,2\n5221,ANTERIOR SEGMENT EYE DISEASES,Eye diseases that affect the front part of the eye,1\n5287,ANTERIOR CORNEAL SEGMENT,The part of the cornea affected by CNV,1\n5288,VISUAL IMPAIRMENT,Potential consequence of CNV,1\n4831,BLINDNESS,\"**Blindness**, a severe form of visual impairment, is often caused by corneal neovascularization, a condition where new blood vessels grow abnormally on the cornea.  This can lead to significant vision loss and impact daily life. \n\",1\n5291,THERMO-SENSITIVE DRUG-LOADED HYDROGEL,New drug delivery method for CNV,1\n1357,HOSPITALIZATIONS,,5\n1358,BLOOD TRANSFUSIONS,,5\n1355,GIAD,Group of patients with GIAD,4\n4405,OSTHOLE,Osthole is a natural coumarin compound,3\n4406,OST-ME,A formulation of Osthole for topical administration,5\n2487,CLINICAL TRIALS,,3\n2433,MCRC,A type of colorectal cancer,3\n2435,JRCTS031180122,,3\n2488,SYSTEMATIC REVIEW AND META-ANALYSIS,,2\n2489,LITERATURE SEARCH,,2\n4407,CAPRYOL-90,Capryol-90 is a surfactant used in OST-ME,1\n4408,CREMOPH,,1\n1354,LVAD,Left Ventricular Assist Device,1\n1359,GI ENDOSCOPIC PROCEDURES,,1\n2494,PLACEBO,Placebo is a control group in medical trials,2\n4409,WATER SOLUBILITY,,2\n1686,MICROPHYSIOLOGY SYSTEM,A system that combines 3D cell culture and deep learning,1\n1688,DEEP LEARNING,\"**Deep Learning** is a type of machine learning that uses artificial neural networks to analyze data, particularly images. \n\",3\n2499,ANTI-VEGF AGENTS,A class of drugs used for treating eye diseases,1\n5222,SLIT-LAMP MICROSCOPE,Device used for examining the anterior segment of the eye,1\n5289,SURGICAL SUTURES,A common treatment for CNV,2\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n493,BEVACIZUMAB,PAZOPANIB,Both medications are used for treating patients with GIAD,20\n496,BEVACIZUMAB,ENDOSCOPIES,Bevacizumab was associated with a decrease in endoscopies for patients with cancer,20\n952,FTD/TPI,BEVACIZUMAB,F.T.D./T.P.I. is a treatment regimen that includes bevacizumab,19\n995,BEVACIZUMAB,OTHER TREATMENTS,Bevacizumab is compared to other treatments for eye disease,19\n942,BEVACIZUMAB,TRIFLURIDINE/TIPIRACIL,Bevacizumab and trifluridine/tipiracil are used in the TRUSTY study,17\n991,BEVACIZUMAB,VISUAL ACUITY,Bevacizumab improves visual acuity after treatment,17\n992,BEVACIZUMAB,CO-NV,\"Bevacizumab improves CoNV severity\nBevacizumab improves CoNV severity compared to placebo\",17\n993,BEVACIZUMAB,GRAFT REJECTION,\"Bevacizumab reduces graft rejection rate compared to placebo\nBevacizumab reduces graft rejection rate\",17\n994,BEVACIZUMAB,FAILURE RATE,\"Bevacizumab reduces failure rate in patients compared to placebo\nBevacizumab reduces failure rate in patients\",17\n982,CORNEAL NEOVASCULARIZATION,VEGETA GROWTH FACTOR INHIBITORS,Corneal neovascularization can be prevented by anti-VEGF drugs,16\n2365,CORNEAL NEOVASCULARIZATION,INVASIVE DRUG INJECTIONS,Invasive drug injections are a treatment for CNV,14\n2293,CORNEAL NEOVASCULARIZATION,ANTERIOR SEGMENT EYE DISEASES,\"A fast and efficient evaluation method is needed for the condition\nCorneal neovascularization is a common sign in anterior segment eye diseases\",13\n2361,CORNEAL NEOVASCULARIZATION,ANTERIOR CORNEAL SEGMENT,CNV affects the anterior corneal segment,13\n2362,CORNEAL NEOVASCULARIZATION,VISUAL IMPAIRMENT,CNV can lead to visual impairment,13\n2363,CORNEAL NEOVASCULARIZATION,BLINDNESS,\"CNV can cause blindness\nCNV can lead to blindness\",13\n2364,CORNEAL NEOVASCULARIZATION,THERMO-SENSITIVE DRUG-LOADED HYDROGEL,New drug delivery method for CNV,13\n500,HOSPITALIZATIONS,BLOOD TRANSFUSIONS,Hospitalizations and blood transfusions were correlated,10\n490,GIAD,HOSPITALIZATIONS,Data on hospitalizations was obtained from first admission for GIB up to a median of 35.7 months following treatment initiation (range 1.3-59.8),9\n497,PAZOPANIB,HOSPITALIZATIONS,Pazopanib was associated with a decrease in hospitalizations for patients with cancer,9\n502,BLOOD TRANSFUSIONS,ENDOSCOPIES,Blood transfusions and endoscopies were correlated,9\n1870,OSTHOLE,OST-ME,\"The OST-ME formulation improves the therapeutic effect of Osthole on CNV\nOsthole was incorporated into the OST-ME formulation to improve its therapeutic effect on CNV after topical administration\",8\n984,VEGETA GROWTH FACTOR INHIBITORS,CLINICAL TRIALS,Clinical trials are conducted to examine the efficacy and safety of anti-VEGF drugs,7\n949,MCRC,FTD/TPI,Patients with mCRC may benefit from FTD/TPI plus bevacizumab,6\n951,MCRC,JRCTS031180122,The study on the effects of FTD/TPI plus bevacizumab in patients with mCRC was conducted by jRCTs031180122,6\n985,VEGETA GROWTH FACTOR INHIBITORS,SYSTEMATIC REVIEW AND META-ANALYSIS,\"Systematic review and meta-analysis is used to examine the efficacy and safety of anti-VEGF drugs\nAnti-VEGF drugs are examined using systematic review and meta-analysis\",6\n986,VEGETA GROWTH FACTOR INHIBITORS,LITERATURE SEARCH,Literature search is used to gather information about anti-VEGF drugs,6\n1874,OST-ME,CAPRYOL-90,Capryol-90 is a surfactant used in the OST-ME formulation,6\n1875,OST-ME,CREMOPH,Cremoph is another ingredient used in the OST-ME formulation,6\n489,LVAD,GIAD,Patients with LVAD and GIAD were included in the analysis,5\n492,GIAD,GI ENDOSCOPIC PROCEDURES,Data on GI endoscopic procedures was obtained from first admission for GIB up to a median of 35.7 months following treatment initiation (range 1.3-59.8),5\n987,CLINICAL TRIALS,SYSTEMATIC REVIEW AND META-ANALYSIS,\"Systematic review and meta-analysis is used to examine the efficacy and safety of anti-VEGF drugs\nClinical trials are conducted to examine the efficacy and safety of anti-VEGF drugs\",5\n997,PLACEBO,OTHER TREATMENTS,Placebo is used as a control group in medical trials,5\n1872,OSTHOLE,WATER SOLUBILITY,\"Osthole is water insoluble, but the OST-ME formulation improves its water solubility\",5\n666,MICROPHYSIOLOGY SYSTEM,DEEP LEARNING,Deep learning is used in the microphysiological system,4\n998,ANTI-VEGF AGENTS,OTHER TREATMENTS,Anti-VEGF agents are compared to other treatments for eye disease,4\n2295,DEEP LEARNING,SLIT-LAMP MICROSCOPE,Used to analyze images from slit-lamp microscope,4\n2367,SURGICAL SUTURES,INVASIVE DRUG INJECTIONS,Both are treatments for CNV,4\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_057c3d04bcff5779d4ac65d9fd057e3b58fa62ec1521946a94ba64cdfae69ffb_v2"}